Joshua Palmer

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, Joshua Palmer sits in the upper half of US sponsors by registered trial count (#4,885 of 15,742 sponsors by registered trial count).

2 total trials 2 currently recruiting early-phase tilt upper half by trial count

Joshua Palmer: 2 sponsored US clinical trials, 2 recruiting.

Joshua Palmer sponsors 2 registered US clinical trials on ClinicalTrials.gov, 2 of them currently recruiting. 0 of these trials are in Phase 3-4 (later-stage) and 2 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Brain Metastases, with 1 trials.

Mid-pack sponsor footprint

Joshua Palmer is in the upper half of sponsors by trial count (#4,885 of 15,742 sponsors by registered trial count). Use the pipeline list and therapeutic areas to see what drives that mid-pack volume.

Open and recent trials

2 total, page 1 of 1

RECRUITING Phase 1

RYZ101 for the Treatment of Progressive or Recurrent Intracranial Meningioma

NCT07150806
RECRUITING Phase 1

Delayed or Upfront Brain RAdiotherapy in Treatment naïve Lung Cancer Patients With Asymptomatic or Minimally Symptomatic Brain Metastases and ALK rEarrangements

NCT05987644

Phase Distribution

PhaseTrial count
Phase 1 2

Therapeutic Areas

Brain Metastases 1
Recurrent Meningioma 1
NSCLC 1
Lung Cancer 1

What is open in the Joshua Palmer pipeline

2 recruiting of 2 indexed (100% open).

Phase mix: 0 late (III/IV) vs 2 early (I/II) (early-phase heavy).

Top condition: Brain Metastases (1 trial), 3 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Joshua Palmer: open-pipeline peers nationwide

Peers matched on 2 registered trials and 100% open enrollment, not the therapeutic-area sidebar.

Joshua Palmer sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 1.522.533.544.5 0%50%100%150% Total trials Recruiting share Joshua Palmer1200 Pharma1ST Biotherapeutics3 Waves Wellness3EO HealthAAVantgarde Bio SrlAcorn BiolabsAcrivon TherapeuticsADARx Pharmaceuticals
Joshua Palmer sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Joshua Palmer sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 2 trials (± recruiting share)

Sponsors near 100% open enrollment (± trial volume)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Joshua Palmer page

2 registered trials is a research-attention snapshot, not an endorsement of Joshua Palmer or any single study.

  • 2 of Joshua Palmer's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Brain Metastases is the condition Joshua Palmer studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Brain Metastases trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Joshua Palmer pipeline card: 2 registered trials from official public datasets.Report a data error.